

FY2008 Third Quarter Business Results

(Year ended March 31, 2009)

January 30, 2009
Nippon Chemiphar Co., Ltd. (4539)

Consolidated Sales and Income

¥mn

	3rd Quarter FY2007		3rd Quarter FY2008			Forecast FY2008	
	Amount	Distrib. (%)	Amount	Distrib. (%)	YOY (%)	Amount	YOY (%)
Sales	15,908	100.0	16,756	100.0	5.3	22,580	74.2
Pharmaceuticals	15,147	95.2	16,287	97.2	7.5	21,800	74.7
Exports	310	—	254	—	(18.2)	380	66.3
Others	761	4.8	469	2.8	(38.4)	780	60.1
Cost of sales	6,579	41.4	7,716	46.1	17.3		
				+4.7points			
SG&A expenses	8,322	52.3	8,640	51.6	3.8		
Operating income	1,006	6.3	399	2.4	(60.3)	530	75.5
Non-operating income	(116)		(192)		(66.5)		
Ordinary income	890	5.6	207	1.2	(76.7)	270	77.0
Net income	479	3.0	21	0.1	(95.6)	160	13.3

Sales of Pharmaceuticals

¥mn

	3rd Quarter FY2007		3rd Quarter FY2008			Forecast FY2008	
	Amount	Distrib. (%)	Amount	Distrib. (%)	YOY (%)	Amount	YOY (%)
Pharmaceuticals	13,808	100.0	14,873	100.0	7.7	19,640	75.7
Core products	6,404	46.4	5,788	38.9	(9.6)	7,630	75.9
Uralyt	2,697		2,625		(2.7)	3,440	76.3
Soleton	3,146		2,660		(15.4)	3,540	75.1
Calvan	561		503		(10.3)	650	77.4
Generics	7,404	53.6	9,085	61.1	22.7	12,010	75.6
Pravastatin	945		919		(2.8)	1,230	74.7
Voglibose	403		625		55.1	820	76.2
Lansoprasole	78		415		5.3times	530	78.3
Others	5,978		7,126		19.2	9,430	75.6